Pharmaceuticals News and Research

RSS

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AstraZeneca and Targacept, Inc. havey announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

10 Dec 2008

Alnylam Pharmaceuticals update on Kreutzer-Limmer patent estate

Alnylam Pharmaceuticals, Inc. has announced that the European Patent Office (EPO) has ruled in favor of the Appellants in oral proceedings before the Board of Appeals related to the '623 (EP 1144623) patent in its Kreutzer-Limmer patent estate.

10 Dec 2008

AcelRx Pharmaceuticals reports positive results in trial of sublingual Sufentanil NanoTabs in treating post-op pain

AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery.

10 Dec 2008

Positive trial results for transdermal Lidocaine system

Phosphagenics Limited has announced the successful completion of a phase 1 clinical trial that examined the ability of its patented drug delivery system, TPM, to topically deliver the pain relief drug, lidocaine, safely into humans.

8 Dec 2008

Changes in medical terminology confuses patients

The label used to identify a disease - whether it is common language or medical terminology - can influence how serious people think the condition is, according to new research from McMaster University, the second part of a larger study on how people understand and interpret disease.

8 Dec 2008

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Laboratories Limited has announced that its flagship product Tetrabenazine, (known as NITOMAN in Germany and other key European territories and XENAZINE in the UK, U.S. and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

8 Dec 2008

An Achilles heel in cancer cells

A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.

8 Dec 2008

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

8 Dec 2008

United States can learn from Dutch healthcare system

The United States can learn from the Dutch Health Insurance System model, according to an article by Pauline V. Rosenau, Ph.D., in the December issue of the Journal of Health Politics, Policy and Law.

8 Dec 2008

RHEI Pharmaceuticals starts final trial of Tibozole in China

RHEI Pharmaceuticals, Inc. has announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China.

8 Dec 2008

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.

8 Dec 2008

ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%

ISTA Pharmaceuticals, Inc. has announced results from the Company's recently completed Phase III clinical program of Xibrom (0.09% bromfenac sodium ophthalmic solution) QD (once-daily).

8 Dec 2008

FDA advisory committee recommends approval of LATISSE as a treatment for hypotrichosis of eyelashes

Allergan, Inc. has announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve LATISSE (bimatoprost solution 0.03%) as a treatment for hypotrichosis (or reduced amount of hair) of the eyelashes.

8 Dec 2008

FDA advisory committee recommends approval for Bausch & Lomb's besifloxacin ophthalmic suspension

The U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee today voted unanimously to recommend approval of Bausch & Lomb's besifloxacin ophthalmic suspension, 0.6%, for the treatment of bacterial conjunctivitis.

8 Dec 2008

Azur Pharma to acquire U.S. rights to Elestrin

Azur Pharma Limited has announced that it has entered into a definitive agreement with BioSante Pharmaceuticals, Inc to acquire U.S. rights to Elestrin.

8 Dec 2008

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Allos Therapeutics, Inc. has announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), at the 50th Annual Meeting of the American Society of Hematology (abstract 261).

8 Dec 2008

New data demonstrates efficacy and tolerability of Carisbamate as an adjunctive therapy for partial onset seizures

Phase III data on carisbamate, an investigational compound recently filed with the FDA for the adjunctive treatment of partial onset seizures (POS) in patients 16 years of age and older, was presented during the poster sessions of the 32nd Annual Meeting of the American Epilepsy Society.

7 Dec 2008

Clinical study shows that drug improves endothelial function in sickle cell disease patients

Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT) Signal, announced today the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients

5 Dec 2008

Treatment fails to improve common form of heart failure

A medication used for high blood pressure does not improve a common form of heart failure, according to new results from a large, international study.

5 Dec 2008

Pharmaceuticals News and Research

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

Alnylam Pharmaceuticals update on Kreutzer-Limmer patent estate

AcelRx Pharmaceuticals reports positive results in trial of sublingual Sufentanil NanoTabs in treating post-op pain

Positive trial results for transdermal Lidocaine system

Changes in medical terminology confuses patients

Cambridge Labs announces Spanish approval of Tetrabenazine

An Achilles heel in cancer cells

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

United States can learn from Dutch healthcare system

RHEI Pharmaceuticals starts final trial of Tibozole in China

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%

FDA advisory committee recommends approval of LATISSE as a treatment for hypotrichosis of eyelashes

FDA advisory committee recommends approval for Bausch & Lomb's besifloxacin ophthalmic suspension

Azur Pharma to acquire U.S. rights to Elestrin

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

New data demonstrates efficacy and tolerability of Carisbamate as an adjunctive therapy for partial onset seizures

Clinical study shows that drug improves endothelial function in sickle cell disease patients

Treatment fails to improve common form of heart failure

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring